Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC

Verma, Chandan; Eremin, Jennifer M; Robins, Adrian; Bennett, Andrew J; Cowley, Gerard P; El-Sheemy, Mohamed A; Jibril, Jibril A; Eremin, Oleg

doi:10.1186/1479-5876-11-16

Table 2 Tregs in the blood of women with LLABCs undergoing NAC and subsequent surgery

From: Abnormal T regulatory cells (Tregs: FOXP3⁺, CTLA-4⁺), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC

Regulatory T Cells
Baseline (B) Levels in LLABCs *Versus* (v) Levels Following Completion of Chemotherapy (CC) in Different Responders
Study Group Comparisons		FOXP3⁺(%)	CD4⁺CD25⁺(AbN)	CTLA-4⁺(%)	CTLA-4⁺(AbN)
Good Pathological
Responders	B	1.39 ± 0.10	249.20 ± 52.00	1.37 ± 0.45	12.67 ± 4.50
[Group I and II] (n = 9)	CC	0.50 ± 0.10	150.00 ± 25.00	0.79 ± 0.20	4.75 ± 1.00
	CCvB	p = 0.033*	NS	NS	p = 0.020*
Poor Pathological
Responders	B	2.17 ± 1.85	170.29 ± 0.10	1.27 ± 0.30	17.4 ± 2.75
[Group III and IV] (n = 7)	CC	1.24 ± 0.30	163.00 ± 50.00	1.10 ± 0.24	9.44 ± 2.00
	CCvB	NS	NS	NS	p = 0.010*
Complete Pathological
Responders [cPR] (n = 6)	cPR	0.45 ± 0.10	150.00 ± 10.00	0.65 ± 15.00	9.75 ± 0.55
Healthy Female Donors (n = 10)	HFDs	0.24 ± 0.02	35.71 ± 2.71	0.21 ± 0.05	4.17 ± 0.75
	cPRvHFDs	p = 0.004**	35.71 ± 2.71	p = 0.015**	p = 0.004**
Baseline (B) Levels in LLABCs *Versus* (v) Levels Post Surgical Resection (SR) in Different Responders
Study Group Comparisons		FOXP3 ⁺ (%)	CD4 ⁺ CD25 ⁺ (AbN)	CTLA-4 ⁺ (%)	CTLA-4 ⁺ (AbN)
Good Pathological Responders
Responders	B	1.39 ± 0.10	249.20 ± 52.00	1.37 ± 0.45	12.67 ± 4.50
[Group I and II] (n = 9)	SR	0.41 ± 0.10	107.33 ± 15.00	0.52 ± 0.10	3.40 ± 1.20
	SRvB	p = 0.022*	p = 0.032*	p = 0.048*	p = 0.010*
Poor Pathological
Responders	B	2.17 ± 1.85	170.29 ± 0.10	1.27 ± 0.30	17.4 ± 2.75
[Group III and IV] n = 7)	SR	0.60 ± 0.15	127.00 ± 12.05	0.75 ± 0.20	4.00 ± 0.50
	SRvB	NS	NS	NS	p = 0.004*
Complete Pathological
Responders [cPR] Healthy Female Donors (n = 10)	cPR	0.38 ± 0.20	105.22 ±12.00	0.50 ± 0.10	9.75 ± 0.55
	HFDs	0.24 ± 0.02	35.71 ± 2.71	0.21 ± 0.05	3.20 ± 1.10
	cPRvHFDs	p = 0.012**	p = 0.003**	p = 0.024**	p = 0.005**

Values (%, AbN) shown for patients are Means ± SDs. *Statistically significant p values. (student independent t-test). NS: Non significant. AbN: Absolute number (cells/μl). Patients studied, n = 16; Good, n = 9; Poor, n = 7; Healthy female donors (HFDs), n = 10. Patients grouped according to pathological responses documented on resected breast specimens.
**Levels significantly greater than documented in HFDs.

Back to article page